Some of these drugs are of great success; for example the kinase inhibitor imatinib, which blocks BCR-ABL tyrosine kinase activity in chronic myelogenous leukemia (CML) [1], or the human epidermal growth factor receptor 2 (HER-2) inhibitors used to treat cancer patients, who aberrantly overexpress epidermal growth factor receptor (EGFR) in the tumor cells [2]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.